Publicaciones en colaboración con investigadores/as de Complejo Hospitalario Torrecárdenas de Almería (16)

2021

  1. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

    BMC Infectious Diseases, Vol. 21, Núm. 1

  2. Do specific antimicrobial stewardship interventions have an impact on carbapenem resistance in Gram-negative bacilli? A multicentre quasi-experimental ecological study: time-trend analysis and characterization of carbapenemases

    The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 7, pp. 1928-1936

2017

  1. Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494

2015

  1. Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 9, pp. 1879-1884

2014

  1. Predictors of early mortality in very elderly patients with bacteremia: A prospective multicenter cohort

    International Journal of Infectious Diseases, Vol. 26, pp. 83-87

2013

  1. Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: A prospective cohort study

    BMC Infectious Diseases, Vol. 13, Núm. 1

2012

  1. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: A propensity score-based analysis

    Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 1, pp. 472-478

  2. The undiagnosed cases of Clostridium difficile infection in a whole nation: Where is the problem?

    Clinical Microbiology and Infection, Vol. 18, Núm. 7

2010

  1. Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals

    Clinical Microbiology and Infection, Vol. 16, Núm. 9, pp. 1408-1413

2008

  1. Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients

    AIDS, Vol. 22, Núm. 8, pp. 923-930

  2. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen

    Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 4, pp. 793-796

  3. Liver toxicity of antiretroviral combinations including atazanavir/ ritonavir in patients co-infected with HIV and hepatitis viruses: Impact of pre-existing liver fibrosis

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 4, pp. 925-932

2007

  1. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients

    Journal of Antimicrobial Chemotherapy, Vol. 60, Núm. 6, pp. 1347-1354

  2. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients

    Antiviral Therapy, Vol. 12, Núm. 8, pp. 1225-1235

2002

  1. Usefulness of sputum culture for diagnosis of bacterial pneumonia in HIV-infected patients

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 21, Núm. 5, pp. 362-367

2000

  1. Haemophilus influenzae pneumonia in human immunodeficiency virus- infected patients

    Clinical Infectious Diseases, Vol. 30, Núm. 3, pp. 461-465